The American Journal of Medicine
Volume 121, Issue 10, Supplement 1 , Pages S32-S34 , October 2008

Where Do We Go From Here?

  • Thomas A. Pearson, MD, MPH, PhD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Thomas A. Pearson, MD, MPH, PhD, Department of Community and Preventive Medicine, University of Rochester Medical Center, 601 Elmwood Avenue, Box 644, Rochester, New York 14642

References 

  1. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;121(Suppl):S3–S8
  2. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(Suppl):S9–S14
  3. Wilson PWF. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med. 2008;121(Suppl):S15–S20
  4. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008;121(Suppl):S21–S31
  5. Borst SE. The role of TNF-α in insulin resistance. Endocrine. 2004;23:177–182
  6. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–2556
  7. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis. 2000;148:209–214
  8. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  9. Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol. 2007;852–858
  10. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:303–305
  11. Choi HK, Hernan MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–1177
  12. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1213–1218
  13. Landewe RB, van den Borne BE, Breedveld FC, et al. Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet. 2000;355:1616–1617
  14. del Rincon I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum. 2005;52:3413–3423
  15. Turesson C, O'Fallon WM, Crowson CS, et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol. 2002;29:62–67

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00593-7

doi: 10.1016/j.amjmed.2008.06.013

The American Journal of Medicine
Volume 121, Issue 10, Supplement 1 , Pages S32-S34 , October 2008

Article Tools